{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T04:44:54Z","timestamp":1787633094266,"version":"build-2736575974"},"reference-count":5,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014942","name":"AveXis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014942","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015277","name":"Roche Products","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015277","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.nmd.2020.03.006","type":"journal-article","created":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T21:37:26Z","timestamp":1587073046000},"page":"267-269","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Randomisation versus prioritisation in a managed access programme: Lessons from spinal muscular atrophy"],"prefix":"10.1016","volume":"30","author":[{"given":"Laurent","family":"Servais","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janbernd","family":"Kirschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Muntoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.nmd.2020.03.006_bib0001","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the Phase 2 Nurture study","volume":"29","author":"De Vivo","year":"2019","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"10.1016\/j.nmd.2020.03.006_bib0002","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.nmd.2019.11.002","article-title":"244th ENMC international workshop: newborn screening in spinal muscular atrophy May 10-12, 2019, Hoofdorp, The Netherlands","volume":"30","author":"Dangouloff","year":"2020","journal-title":"Neuromuscul Disord"},{"issue":"14","key":"10.1016\/j.nmd.2020.03.006_bib0003","doi-asserted-by":"crossref","first-page":"e1312","DOI":"10.1212\/WNL.0000000000006281","article-title":"Nusinersen in patients older than 7 months with spinal muscular atrophy type 1: a cohort study","volume":"91","author":"Aragon-Gawinska","year":"2018","journal-title":"Neurology"},{"issue":"18","key":"10.1016\/j.nmd.2020.03.006_bib0004","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-Dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2020.03.006_bib0005","doi-asserted-by":"crossref","first-page":"m580","DOI":"10.1136\/bmj.m580","article-title":"Health ministers condemn Novartis lottery for Zolgensma, the world's most expensive drug","volume":"368","author":"Dyer","year":"2020","journal-title":"BMJ"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896620300821?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896620300821?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:09:32Z","timestamp":1760774972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896620300821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":5,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0960896620300821"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2020.03.006","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomisation versus prioritisation in a managed access programme: Lessons from spinal muscular atrophy","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2020.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}